Please login to the form below

Not currently logged in
Email:
Password:

Restasis

This page shows the latest Restasis news and features for those working in and with pharma, biotech and healthcare.

Court throws out Allergan's patent deal with Native American tribe

Court throws out Allergan's patent deal with Native American tribe

Court throws out Allergan's patent deal with Native American tribe. Rules the contentious agreement can't protect its dry eye treatment Restasis. ... A US judge has sent Allergan into a spin following a ruling on patents protecting its blockbuster dry

Latest news

  • Shire files dry eye drug lifitegrast in Europe Shire files dry eye drug lifitegrast in Europe

    Xiidra was brought to market with a broader label than its main rival - Allergan's Restasis (cyclosporine) - and made $96m in sales in the first half of 2017 with Shire claiming ... The drug still has a long way to go to catch up Restasis, although

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    last year, challenging a market for drug treatments currently dominated by Allergan’s $1.4bn product Restasis (cyclosporine).

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    Shire launches dry eye drug Xiidra in US. Sparks rivalry with Allergan’ s blockbuster Restasis as first new dry eye treatment in 13 years. ... That gives Xiidra a broader label than Restasis (cyclosporine) that analysts suggest could catapult it to

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    year. Allergan's Restasis (cyclosporine ophthalmic emulsion) is the major player in dry eye disease – but Shire will hope that it can quickly establish a considerable foothold.

  • FDA deals a big blow to Shire's late-stage pipeline FDA deals a big blow to Shire's late-stage pipeline

    Dry eye disease was something of a wasteland for drug developers for many years, although that changed when Allergan won approval for its Restasis (cyclosporine ophthalmic emulsion) product, which has become ... tolerate Restasis or are not satisfied

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    In second position, Allergan experienced modest sales growth of 2.3%. “Allergan’s main ophthalmology product - Restasis - is the go-to treatment for dry eye, but is due to go off

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    To defend its dry eye treatment Restasis (ciclosporin) against generic competition, Allergan has transferred the patent to the St Regis Mohawks, who have 'sovereign immunity' under US law. ... The Restasis case is not so much an example of 'evergreening'

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics